Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 115

Results For "TD"

1253 News Found

Pfizer posts Q1FY22 PAT of Rs. 199.91 Cr
News | July 29, 2021

Pfizer posts Q1FY22 PAT of Rs. 199.91 Cr

The company posted net profit of Rs.124.45 crores for the period ended June 30, 2020.


Aarti Drugs posts Q1FY22 consolidated PAT at Rs. 48.81 Cr
News | July 28, 2021

Aarti Drugs posts Q1FY22 consolidated PAT at Rs. 48.81 Cr

The company posted net profit f Rs.85.45 crores for the period ended June 30, 2020.


Granules India Q1FY22 consolidated net profit at Rs. 120.20 Cr
News | July 28, 2021

Granules India Q1FY22 consolidated net profit at Rs. 120.20 Cr

The company posted net profit of Rs.111.44 crores for the period ended June 30, 2020.


Bharat Immunologicals and Biologicals Corporation Q1FY22 net profit at Rs. 1.92 Cr
News | July 28, 2021

Bharat Immunologicals and Biologicals Corporation Q1FY22 net profit at Rs. 1.92 Cr

The company reported total income Rs.18.57 crores during the period ended June 30, 2020.


GlaxoSmithKline delivers 19% revenue growth for Q1 FY22
News | July 27, 2021

GlaxoSmithKline delivers 19% revenue growth for Q1 FY22

The company has decided to transfer our rights in relation to the lodex and Ostocalcium brands to GlaxoSmithKline Asia Private Limited


Biocon Biologics partners Adagio to manufacture antibody for COVID-19
News | July 27, 2021

Biocon Biologics partners Adagio to manufacture antibody for COVID-19

ADG20, a novel monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses


Lonza reports strong momentum in H1 2021
News | July 24, 2021

Lonza reports strong momentum in H1 2021

The company confirms an upward revision to its 2021 Outlook, reflecting the expectation to achieve mid-teens CER sales growth


Biocon Q1FY22 revenue up 6% at Rs 1,808 Cr
News | July 23, 2021

Biocon Q1FY22 revenue up 6% at Rs 1,808 Cr

Q1 FY22 consolidated revenue grew 6% to Rs. 1,808 crore from Rs. 1,712 crore in Q1 FY21. Q1 FY22 Net Profit was Rs. 84 crore (vs. Rs. 149 crore in Q1 FY21).


Gland Pharma Q1FY22 consolidated PAT rises to Rs. 350.65 Cr
News | July 22, 2021

Gland Pharma Q1FY22 consolidated PAT rises to Rs. 350.65 Cr

The company reported total income of Rs.1215.73 crores during the period ended June 30, 2021.


Cadila Healthcare completes sale of animal healthcare business
News | July 16, 2021

Cadila Healthcare completes sale of animal healthcare business

The company had announced the expected date of completion of sale and disposal of the said undertaking is 90 days from the date of signing the Definitive Agreements.